Search PubMed⌕ Search

Biomedical subjects

H Oi

Publications and source records attributed to H Oi.

At least 19 recordsLinked to original sources
PubMed1992

[CT assessment of gallbladder opacification 12-24 hours after angiography].

After the injection of conventional contrast agents that are largely excreted in urine, gallbladder opacification is observed in patients with renal dysfunction. However, some reports have noted that gallbladder opacification on plain radiographs occurs frequently in patients without renal impairment after the intravenous administration of Ioxaglate, one of the new low-osmolality agents. We carried out CT examination 12-24 hours after angiography with various kinds of contrast media in 437 patients to examine the incidence of gallbladder opacification. The influence of hepatobiliary and renal function on the excretion of contrast medium is discussed. Gallbladder opacification was observed in more than 60% of the patients. This result indicates that gallbladder opacification is not a rare phenomenon, and is even common in delayed CT examinations of patients with normal renal function. The high frequency of gallbladder opacification was recognized not only in the renal dysfunction group but also in the normal liver function group. Gallbladder opacification in delayed CT examination shows that the hepatobiliary tract is important in the excretion of contrast medium.

Adolescent↗
PubMed1992

[Image-transmission using 64 kbps-ISDN (Integrated Services Digital Network) and mini-PACS].

We carried out the image-transmission using 64kbps-ISDN between two image workstations (IWS) of mini-PACS installed at the Department of Radiology, Osaka Teishin Hospital and the Kashiwa Works, Hitachi Medical Corporation. The distance between Osaka and Kashiwa is about 600 km. The subtraction of two images before and after transmission revealed no change of the data of the image during transmission. For 1/2 compression image, the times of image-transmission of 256 x 256, 320 x 320 and 512 x 512 matrix were 9, 17 and 33 second, respectively. The efficiency of image-transmission was about 80%. Using ISDN, we can make an accurate, rapid and cheap image-transmission.

Computer Communication Networks↗
PubMed1992

Efficacy of combination treatment--(TAE with adriamycin and ethanol)--for hepatocellular carcinoma.

Among 44 patients with hepatocellular carcinoma (HCC), combination treatment with both transhepatic arterial embolization (TAE) and ethanol injection therapy (EIT) was performed in 10 patients. Only two had tumors measuring less than 3 cm in diameter. In all, eight patients had solitary tumors and two had multiple tumors. The tumor was classified as stage I in one patient, stage II in six subjects, stage III in two patients, and stage IV in one subject prior to TAE, but one stage II case was changed to stage III after laparotomy. The clinical stage was I in two patients, II in six subjects and III in two patients. Five patients with tumors of stages I and II achieved either a complete response (CR) or partial response (PR). However, three patients with tumors of stages III and IV showed progressive disease (PD). Thus, the response rate (CR+PR) was 50%. For tumor stages I and II, the 1-, 2-, and 3-year survival values were 100%, 100%, and 83%, respectively. For tumor stages III and IV, the 1- and 2-year survival values were 75% and 25%, respectively. Combination treatment of HCC appears to be efficacious for tumor stages I and II.

Adult↗
PubMed1992

Outcome of localized hepatocellular carcinoma treated with segmental arterioportal chemoembolization.

When lipiodol is injected into the hepatic artery at a dose exceeding a certain level, it flows into the portal vein. On the basis of this feature, an emulsion of Adriamycin with lipiodol was injected into a segmental or subsegmental artery such that it was delivered to the portal vein of the same segment, and the artery was then embolized with Gelfoam. This segmental arterioportal chemoembolization (cement therapy) was performed in 50 patients with localized hepatocellular carcinoma. A posttreatment CT scan showed that almost 100% of the lesions were occupied by lipiodol. The cumulative survival values determined for the 50 patients were very high: 83.4% after 1 year and 62.7% after 2 years.

Adult↗
PubMed1991

Prevention of gastric complications in hepatic arterial chemoembolization. Balloon catheter occlusion technique.

Gastric complications may be a problem in transcatheter arterial chemoembolization, if the right gastric artery branches distally from the proper hepatic artery or its branch, or the accessory left gastric artery arises from the left hepatic artery. We occluded the proper hepatic artery with a balloon catheter to redirect blood flow in these gastric branches toward the liver. This procedure prevented chemoembolic agents from flowing into the gastric branches, and accordingly protected against gastric complications even when chemoembolization was performed by injecting the agents proximally to the gastric branches.

Carcinoma, Hepatocellular↗
PubMed1990

Hepatic neoplasms: effects of transcatheter arterial embolization on coagulation and fibrinolysis.

Forty-eight patients with hepatic malignancy (47 with hepatocellular carcinoma, one with metastatic colon carcinoma), who underwent transcatheter arterial embolization (TAE) for treatment of hepatic neoplasms, were investigated to determine the effects of TAE on coagulation and fibrinolysis. TAE was followed by a significant decrease in the platelet count (P less than .001); a prolongation of prothrombin time (P less than .001); an early increase in levels of fibrinopeptide A (P less than .01), fibrinopeptide B beta-15-42 (P less than .001), and fibrin(ogen) degradation products (P less than .001); and a delayed increase in the fibrinogen level (P less than .001), without a significant prolongation of the activated partial thromboplastin time. In the three patients who developed disseminated intravascular coagulation (DIC) after TAE, a reduction of both the platelet count and fibrinogen level occurred significantly earlier and in a more severe form than in the other patients without DIC; this reduction preceded the onset of the characteristic symptoms of DIC. Data suggested that close monitoring of platelet count and fibrinogen level is important for early detection of DIC following TAE.

Adult↗
PubMed1990

Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins.

Hepatocellular carcinoma was treated with slow injection of an emulsion containing 40 to 60 mg of adriamycin and 3.5 to 12 ml of Lipiodol into the portal vein via a segmental hepatic artery. During and after the injection, the portal branches of the segment were demonstrated. Six patients with resectable hepatocellular carcinoma received this treatment, which in 3 of them was followed by embolization with Gelfoam of the segmental artery. In these 3, all main tumors and daughter nodules became completely necrotic, but some infarction developed in the non-tumorous area. Those without Gelfoam had complete necrosis of all daughter nodules, but incomplete response of the main tumor. This combined treatment may be recommended for patients with localized lesions which are nonresectable due to cirrhosis, or for other reasons.

Aged↗
PubMed1989

Transcatheter oily chemoembolization of hepatocellular carcinoma.

Since 1983, transcatheter oily chemoembolization (TOCE) with doxorubicin hydrochloride, iodized oil, and gelatin sponge was used in 100 patients with hepatocellular carcinoma. Doxorubicin, 40-100 mg (mean, 61.3 mg), was mixed with 5-20 mL (mean, 9.6 mL) of an iodized oil to prepare a water-in-oil emulsion that was then infused into the hepatic artery. Both progressive changes in blood concentrations of doxorubicin and its tissue concentrations in patients who underwent hepatectomy demonstrated that the drug was released slowly from the emulsion. The cumulative survival rate was 82.0% for 6 months, 53.8% for 1 year, 33.3% for 2 years, and 17.6% for 3 years. These survival rates were better than those of 104 patients who underwent embolization with gelatin sponge, then received an anticancer drug (67.4% for 6 months, 45.2% for 1 year, 16.3% for 2 years, and 3.8% for 3 years).

Carcinoma, Hepatocellular↗
PubMed1989

[Limitation of oily chemoembolization against hepatocellular carcinoma and arterioportal segmental chemoembolization].

Emulsion of adriamycin and lipiodol added with Gelfoam has been used for the transcatheter oily chemoembolization against hepatocellular carcinomas. This therapy resulted in significantly increased cumulative survival as compared with chemoembolization therapy using anti-cancer drugs and Gelfoam. However, it was revealed to have the following limitations: Insufficient efficacy against micrometastases and extracapsular invasion; impossible to perform sufficient treatment for patients with severe hepatic disorders; and there were cases in which lipiodol was hardly retained. In order to overcome the limitations described above, we have performed segmental hepatic chemoembolization simultaneously from the hepatic artery embolization simultaneously from the hepatic artery and portal vein. This method works on the basis of the fact that excess amount of lipiodol emulsion infused from the hepatic artery flows into the portal vein. Gelfoam embolization is also added in this method. Though subjects appropriate for this newly developed method are restricted, all the tumors in the objective segment of the liver can undergo necrosis. The efficacy is comparable to the effects of hepatectomy. In addition, since the other segments of the liver are able to be kept in reserve, this method is able to be applied to patients with severe hepatic disorders.

Aged↗
PubMed1989

[Segmental arterio-portal chemo-embolization in hepatocellular carcinoma (cement therapy)].

When a large amount of iodized oil (LPD) is selectively administered to targeted segments of the liver, the tumor vessels and sinusoids around the tumor are filled with LPD, subsequently regurgitating excessive LPD via the hepatic arterioportal communication into the portal branches surrounding the tumor. Segmental arterioportal chemoembolization in HCC with Doxorubicin-in-oil emulsion (DOE), which we named cement therapy, was performed in 18 patients with HCC. DOE was administered selectively into one segment division of Couinaud in ten patients, two segments in seven and three segments in one. Computed tomography and ultrasonography following the cement therapy revealed an overall response rate of 39%. The one-year cumulative survival rate was 80%, and that for three-years was 33%. Three cases underwent segmental hepatectomy and these specimens revealed total necrosis of the main tumor and whole daughter nodules, followed by various degrees of hepatic parenchymal infarction. This cement therapy realizes the simultaneous chemoembolization via the artery and portal vein, and was considered an effective treatment for extra-capsular infiltration and daughter nodules of HCC nourished by the portal vein blood flow. Limited administration of DOE to the targeted segments enables transarterial oily chemoembolization (TOCE) without any serious side effects.

Adult↗
PubMed1988

Iodized oil in the portal vein after arterial embolization.

Transcatheter embolization with a relatively large amount (average, 17 mL) of iodized oil and doxorubicin hydrochloride with or without gelatin sponge particles was performed in 50 patients with hepatocellular carcinoma and in eight patients with liver metastases. After an intraarterial hepatic injection of an emulsion of iodized oil and doxorubicin hydrochloride, iodized oil was seen in the portal vein; the amount correlated with the amount that was injected, despite the lack of arterioportal shunting. Prominent portal vein appearances were seen in six of 21 cases (29%) given 10 mL or less of iodized oil, in 14 of 21 cases (67%) with 10-20 mL, and in 18 of 21 cases (86%) with more than 20 mL. Iodized oil may enter the portal vein through an arterioportal communication after pooling in the sinusoids.

Animals↗
PubMed1987

Balloon-occluded arterial portography using prostaglandin E1: improved visualization of the intrahepatic portal vein.

For improved visualization of the intrahepatic portal vein, balloon-occluded superior mesenteric arteriography was performed using a torque-controlled balloon catheter after injection of 20 micrograms prostaglandin E1. In patients who underwent arterial portography twice, i.e., by the method using prostaglandin E1 alone and the prostaglandin E1 plus the balloon method, the latter method provided better visualization, particularly in cases in which an aberrant right hepatic artery arose from the superior mesenteric artery.

Alprostadil↗
PubMed1987

[Oily chemoembolization of hepatoma].

Since 1983 we have performed transcatheter oily chemoembolization (TOCE) using adriamycin (40-100 mg), Lipiodol (5-20 ml) and Gelfoam in the treatment of 100 cases with unresectable hepatocellular carcinoma. Adriamycin was dissolved in a fluid equal in specific gravity to Lipiodol and the adriamycin solution was mixed with 3 volumes of Lipiodol, making an adriamycin-in-oil emulsion (AOE). After TOCE, the blood concentration of adriamycin was obviously lower than that after one-shot injection because of the slow release of adriamycin from the AOE. Also, in cases of hepatic resection after TOCE, there was a clear difference in the adriamycin concentration between the tumor and the normal hepatic tissue. The cumulative survival rates for the 100 patients treated by TOCE were: 6 months 81.9%, 1 year 53.8% and 2 years 36.5%. Thus, improvement was found in comparison with the cumulative survival rates for 104 patients who underwent hepatic embolization without Lipiodol, which were 6 months 67.4%, 1 year 45.2% and 2 years 16.3%. AOE retained in the tumor as microemboli brings about the slow-releasing effect of adriamycin. Furthermore, by adding the effect of Gelfoam embolization, TOCE has a strong antitumor effect.

Carcinoma, Hepatocellular↗
PubMed1987

[Chemoembolization].

Chemoembolization is a technique by which the blood flow in the artery feeding a tumor is arrested and, at the same time, an antitumor agent is delivered in a high concentration to the target site in anticipation of a synergistic antitumor effect. Usually, this is a transcatheter technique. The embolic materials used to arrest the blood flow include gelatin sponge, Lipiodol, microcapsule, albumin microsphere, degradable starch microsphere and the like. Since the gelatin sponge and Lipiodol are available on the market, transcatheter oily chemoembolization (TOCE) using these two materials was performed in cases of hepatic tumor. In many cases of TOCE, adriamycin was used as an adriamycin solution Lipiodol mixture (adriamycin-in-oil emulsion). The cumulative survival rates for 100 patients with unresectable hepatoma treated by TOCE were 53.8% for one year and 36.5% for two years. Thus, improvement was observed in comparison with the cumulative survival rates of 104 patients who underwent hepatic embolization without Lipiodol (1 year, 45.2%, 2 years, 16.3%). Adriamycin-in-oil emulsion retained in the tumor as microemboli brings about the slow-releasing effect of adriamycin. The effect was demonstrated in the blood and tissue concentrations of adriamycin following TOCE.

Aged↗